Anti-Müllerian hormone levels before and after uterine artery embolization. Issue 3 (4th May 2018)

• Record Type: Journal Article
• Authors: McLucas, Bruce; Voorhees, William D.; Snyder, Scott A.
• Is Part Of: Minimally invasive therapy & allied technologies. Volume 27:Issue 3(2018)
• Page Start: 186
• Page End: 190
• Publication Date: 2018-05-04
• Subjects: Anti-Müllerian hormone -- fertility -- embolization -- uterine artery embolization; Endoscopy -- Periodicals; Interventional radiology -- Periodicals; Endoscopic surgery -- Periodicals; 617.05
• DOI: 10.1080/13645706.2017.1365728
• Languages: English
• ISSNs: 1364-5706

Abstract

Abstract: Objective: To determine the effects of uterine artery embolization (UAE) on ovarian reserve as measured by Anti-Müllerian hormone (AMH) levels. Material and methods: Non-randomized, observational study of 89 women 23–40 years of age who received UAE. Control hormone levels were measured prior to UAE and the first post-embolization measurement was taken at various times post-procedure (mean = 190 ± 229 days). Results: Historical work verified by our earlier work has shown that AMH levels decline with age. Regression analysis allows us to determine whether UAE contributes to a greater decline in AMH values over that naturally occurring with aging. The effect of the procedure was found to contribute no deleterious effect to the natural decline in AMH levels. In addition, multiple blood draws were obtained from 32 patients up to 47 months post-UAE. Regression studies with these patients as their own controls showed no long-term diminishment of ovarian reserve due to the UAE procedure. Conclusions: Earlier reported data are consistent with larger sample size. UAE does not affect ovarian reserve in women <40 as evidenced by no significant change in AMH levels after embolization. Women who are of reproductive age and have uterine fibroids can consider UAE without concern for adverse effects on their fertility.